Gelteq Ltd GELS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.44 down $0.02, 3.42% at close Nov 6
Last close · Previous close $0.46
- Market cap
- $4.71MAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$0.44down $0.14, 24.10%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.46Nov 5
- Volume24.68KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume77.40KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.39 to $2.01; now $0.44
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
GELS trailed the S&P 500 in all 4 periods.
| Period | GELS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GELS: down 24.1% S&P 500: down 5.6% | GELS trailed the S&P 500 by 18.5 percentage points Trailed |
| 3M | GELS: down 23.3% S&P 500: down 4.1% | GELS trailed the S&P 500 by 19.2 percentage points Trailed |
| YTD | GELS: down 45.0% S&P 500: up 8.7% | GELS trailed the S&P 500 by 53.7 percentage points Trailed |
| 1Y | GELS: down 58.9% S&P 500: up 10.9% | GELS trailed the S&P 500 by 69.8 percentage points Trailed |
$10,000 invested in GELS a year ago (Nov 6, 2025) would be worth about $4,112 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
GELS trailed the S&P 500 in all 4 periods.
| Period | GELS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GELS: down 24.1% S&P 500: down 5.6% | GELS trailed the S&P 500 by 18.5 percentage points Trailed |
| 3M | GELS: down 23.3% S&P 500: down 4.3% | GELS trailed the S&P 500 by 19.0 percentage points Trailed |
| YTD | GELS: down 45.0% S&P 500: up 7.8% | GELS trailed the S&P 500 by 52.8 percentage points Trailed |
| 1Y | GELS: down 58.9% S&P 500: up 9.7% | GELS trailed the S&P 500 by 68.6 percentage points Trailed |
$10,000 invested in GELS a year ago (Nov 6, 2025) would be worth about $4,112 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$4.79
Closing high on . Now 90.8% below that record.
Split-adjusted daily closes since Oct 29, 2024.
Stock splits
GELS hasn’t split since its price history begins in 2024.
Valuation
The Nov 6 close compared with reported results. 12-month figures aren’t available until four quarters are reported. Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not available
12-month figures aren’t available until four quarters are reported.
Other valuation measures
- 0.5×Book value as of Dec 31, 2025
Price relative to accounting equity (book value) per share on the Dec 31, 2025 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - $8.23MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Dec 31, 2025 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own GELS DCF in Excel. Value Gelteq with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Dec 31, 2025, and balance-sheet figures are as of Dec 31, 2025. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY21 (Jun 30, 2021) | Not reported | Not reported | Not reported |
| Q4 FY22 (Jun 30, 2022) | Not reported | Not reported | Not reported |
| Q4 FY23 (Jun 30, 2023) | $0.00 | −$653.68K | Not reported |
| Q3 FY24 (Mar 31, 2024) | Not reported | Not reported | Not reported |
| Q4 FY24 (Jun 30, 2024) | $0.00 | −$755.42K | Not reported |
| Q2 FY25 (Dec 31, 2024) | Not reported | Not reported | Not reported |
| Q4 FY25 (Jun 30, 2025) | Not reported | Not reported | Not reported |
| Q2 FY26 (Dec 31, 2025) | Not reported | Not reported | Not reported |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Jun 30, 2021) | $0.00 | −$487.91K | −$0.17 |
| FY22 (Jun 30, 2022) | $102.46K | −$2.34M | −$0.32 |
| FY23 (Jun 30, 2023) | $55.06K | −$2.42M | −$0.30 |
| FY24 (Jun 30, 2024) | $0.00 | −$2.36M | −$0.29 |
| FY25 (Jun 30, 2025) | $108.98K | −$4.37M | −$0.47 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $6.27KAs of Dec 31, 2025
Cash plus short- and long-term marketable securities on the Dec 31, 2025 balance sheet.
- Total debt$3.43MAs of Dec 31, 2025
- Net debt$3.43MAs of Dec 31, 2025
- 0.09As of Dec 31, 2025
Current assets divided by current liabilities on the Dec 31, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.36As of Dec 31, 2025
Total debt divided by shareholders’ equity on the Dec 31, 2025 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Gelteq Ltd
Headquartered in Melbourne, Australia, Gelteq is a global biotechnology company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Australia
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
GELS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
GELS stock FAQ
What is GELS stock’s price today?
Gelteq (GELS) traded at $0.44 at the close on , down $0.02 (3.42%) from the previous close of $0.46. Over the past 52 weeks it has traded between $0.39 and $2.01.
What is Gelteq’s market cap?
Gelteq’s market capitalization is about $4.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.44 (how market cap works). Gelteq reported 10.71M shares outstanding at the end of its latest quarter ().
Does GELS pay a dividend?
Gelteq hasn’t paid a dividend in the last twelve months.
What is GELS’s 52-week high and low?
Over the past 52 weeks GELS has traded as low as $0.39 and as high as $2.01. At $0.44 at the close on , it is 78.1% below that high and 13.7% above the low.
What is GELS’s all-time high?
GELS’s highest closing price was $4.79 on , adjusted for stock splits. At $0.44 at the close on , it is 90.8% below that record.
Has GELS stock ever split?
No. GELS hasn’t split since its price history begins in 2024.
How has GELS stock performed?
Including dividends and measured to the close on , GELS has returned −45.0% so far this year and −58.9% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is Gelteq in?
Gelteq is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Australia.
What exchange does GELS trade on?
Gelteq trades on the Nasdaq under the ticker symbol GELS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.